- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance - Results from more than 1,000 high-risk patients were consistent with previous data - Findings from BLAZE-4 trial provide data on lower doses of bamlanivimab and etesevimab together - Media and

INDIANAPOLIS , Jan. 21, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in

RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- The U.S.   Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death

INDIANAPOLIS , Jan. 11, 2021 /PRNewswire/ -- Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease compared

Study will provide real-world data and insight on various infusion setting experiences Plan to study bamlanivimab in a diverse group of participants, including Native American communities INDIANAPOLIS , Dec. 18, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced plans to begin

- New IDEAS study will focus on African American and Latino participants - Study to further assess the utility of amyloid brain PET scans for Alzheimer's Disease and other causes of cognitive decline INDIANAPOLIS , Dec. 14, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) today announced

INDIANAPOLIS , Dec. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that The New England Journal of Medicine   has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy

Pre-planned primary outcome analysis continues to show clinically significant improvement in invasive disease-free survival as data mature for people with HR+, HER2- high risk early breast cancer New data presented includes an additional 3.6 months of follow-up and more than 1400 patients

More than half of participants taking the highest dose achieved normal A1C levels, a key secondary endpoint in first phase 3 trial of SURPASS program Participants in this monotherapy study had relatively recently diagnosed diabetes, with a mean duration of 4.7 years INDIANAPOLIS , Dec.

62% overall response rate in BTK pre-treated CLL/SLL patients, rising to 84% in patients followed for 10 or more months; consistent response rates regardless of reason for prior BTK discontinuation or BTK mutation status Similar overall response rates observed in patients previously treated with